| pubmed-article:1960551 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0004057 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0023516 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0007134 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:1960551 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:1960551 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:1960551 | pubmed:dateCreated | 1992-1-9 | lld:pubmed |
| pubmed-article:1960551 | pubmed:abstractText | We performed a prospective, controlled trial of recombinant leukocyte A interferon (IFN-alpha 2A) with or without aspirin (ASA) in 176 patients with assessable advanced renal cell cancer in light of a 34% response rate (10 of 29 patients) from the two-agent regimen in an earlier nonrandomized trial. This encouraging result was substantially higher than the 15% response rate typically achieved with IFN therapy alone. Eighty-seven patients received IFN-alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week, and 89 received the same IFN therapy with ASA 600 mg orally four times each day. Each group was balanced as to relevant prognostic discriminants. Response rates were 8% for the group receiving ASA in addition to IFN, and 13% for the group receiving IFN alone (P = .30). The median times to progression were 1.9 months for the group receiving IFN with ASA and 2.7 months for the group receiving IFN alone (log-rank P = .36). The median survival durations were 8.8 months for the IFN and ASA group and 8.0 months for the IFN-only group (log-rank P = .60). These figures are also inferior to those typically reported from other studies. Our findings reemphasize the crucial role of randomized trials, admittedly cumbersome and time-consuming, to determine accurately the value of apparently promising therapies. Although some patients may derive benefit from IFN therapy, our findings raise disturbing questions regarding the potential IFN-alpha 2A according to the dose and schedule used in this trial to have any substantive impact on the ultimate outcome of disseminated renal cell cancer. | lld:pubmed |
| pubmed-article:1960551 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1960551 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1960551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1960551 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1960551 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1960551 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:BurokerT RTR | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:CreaganE TET | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:JohnsonP SPS | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:FlaumM AMA | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:TwitoD IDI | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:SchaidD JDJ | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:JohanssonS... | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:VeederM HMH | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:GeeraertsL... | lld:pubmed |
| pubmed-article:1960551 | pubmed:author | pubmed-author:GesmeD HDHJr | lld:pubmed |
| pubmed-article:1960551 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1960551 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:1960551 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1960551 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1960551 | pubmed:pagination | 2104-9 | lld:pubmed |
| pubmed-article:1960551 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:meshHeading | pubmed-meshheading:1960551-... | lld:pubmed |
| pubmed-article:1960551 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1960551 | pubmed:articleTitle | A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. | lld:pubmed |
| pubmed-article:1960551 | pubmed:affiliation | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905. | lld:pubmed |
| pubmed-article:1960551 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1960551 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1960551 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1960551 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1960551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1960551 | lld:pubmed |
